Directly or indirectly, cancer will touch everyone's lives. There is no greater or more worthwhile challenge than the ongoing battle to develop and improve anti-cancer treatments, for everyone's sake.
 |
University of Bradford
At Bradford, YCR funds a large drug discovery Programme at the Institute of Cancer Therapeutics.
.JPG)
Evidence of microtubule damage in HUVECs treated with an ICT developed anticancer agent and immunolabelled with an antibody to α-tubulin (red), with Hoechst nuclear counterstain (blue).
YCR science overview 2002/3
YCR science overview 2003/4
YCR science overview 2004/5
YCR science overview 2005/6
YCR science overview 2006/7
YCR science overview 2007/8
Programme of research 2001/2
Programme of research 2002/3
Programme of research 2003/4
No programme of research in 2004/5
Programme of research 2005/6
Programme of research 2006/7
Programme of research 2007/8
Programme of research 2008/9
Publications 2001/2
No publications in 2002/3
No publications in 2003/4
No publications in 2004/5
No publications in 2005/6
Publications 2006/7
Publications 2007/8
Publications 2008/9
Reports 2001/2
Reports 2002/3
Reports 2003/4
No reports 2004/5
Reports 2005/6
Reports 2006/7
Reports 2007/8
Reports 2008/9
|